Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPARTAN: lasmiditan versus placebo for acute migraine
2015-005689-40Phase 3Completed
- Sponsor
- CoLucid Pharmaceuticals
- Start
- Jul 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of lasmiditan in migraine (4 arms), sponsored by CoLucid Pharmaceuticals. Primary endpoint: Headache pain free at 2 hours post dose. Started Jul 2016; status: completed.
02
Drugs
lasmiditan
03
Conditions
migraine
Beyond the preview
Go deeper on 2015-005689-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-005689-40.